IceCure Medical Ltd ICCM
Set alert
0.87 USD 0.00 -0.01%
As of Nov 2, 12:45 PM ET
0.87 Day range 0.899
0.82 52-week range 23.49
- YTD
- -95.25%
- 1 year
- -95.93%
- Open
- 0.8701
- Prev close
- 0.8701
- Mkt cap
- 4.04M
- Vol
- 31.73K
- Avg vol
- 145.54K
- EPS
- -6.84
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.87
- High
- 0.899
- Forward P/E
- -4.48
- Beta
- 2.63
- Short ratio
- 0.46
- Inst. own
- 0.40%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 20, 2024
- 50-d avg
- 0.74766
- 200-d avg
- 0.852735
- 1y target
- 3.37
5Y chart
Events in this range
- Apr 3, 2024Earnings: -0.07; estimate 0; surprise —%
- May 28, 2024Earnings: —; estimate -0.08; surprise —%
- May 28, 2024Earnings: -0.08; estimate -0.08; surprise 0%
- Jun 5, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Jul 2, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Aug 20, 2024Earnings: —; estimate -0.07; surprise —%
- Aug 20, 2024Earnings: -0.06; estimate -0.07; surprise 14.29%
- Aug 21, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Sep 12, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Nov 8, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Nov 26, 2024Earnings: -0.08; estimate -0.07; surprise -14.29%
- Nov 27, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Jun 4, 2026Split: 1 for 30
Signals (83)
| Name | Date | Ago |
|---|---|---|
| RSI: Oversold | Aug 17, 2026 | 2 months ago |
| RSI: Oversold | Jul 20, 2026 | 3 months ago |
| MACD: Buy Signal | Jun 29, 2026 | 4 months ago |
| RSI: Oversold | May 4, 2026 | 6 months ago |
| RSI: Oversold | Apr 20, 2026 | 6 months ago |
| SMA: Bearish | Mar 23, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 23, 2026 | 7 months ago |
| RSI: Oversold | Mar 23, 2026 | 7 months ago |
| SMA: Bullish | Mar 2, 2026 | 8 months ago |
| MACD: Buy Signal | Mar 2, 2026 | 8 months ago |
| MACD: Sell Signal | Jan 26, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 19, 2026 | 9 months ago |
| SMA: Bearish | Jan 12, 2026 | 9 months ago |
| SMA: Bullish | Jan 5, 2026 | 10 months ago |
| MACD: Sell Signal | Oct 6, 2025 | 1 year ago |
| SMA: Bearish | Sep 29, 2025 | 1 year ago |
| SMA: Bullish | Sep 15, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 15, 2025 | 1 year ago |
| SMA: Bearish | Sep 8, 2025 | 1 year ago |
| SMA: Bearish | Sep 1, 2025 | 1 year ago |
| SMA: Bullish | Aug 25, 2025 | 1 year ago |
| SMA: Bullish | Aug 25, 2025 | 1 year ago |
| SMA: Bearish | Jul 28, 2025 | 1 year ago |
| SMA: Bullish | Jul 21, 2025 | 1 year ago |
| SMA: Bearish | Jul 14, 2025 | 1 year ago |
| SMA: Bullish | Jun 30, 2025 | 1 year ago |
| SMA: Bearish | May 5, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 24, 2025 | 1 year ago |
| SMA: Bearish | Mar 17, 2025 | 1 year ago |
| RSI: Overbought | Mar 10, 2025 | 1 year ago |
| RSI: Overbought | Feb 10, 2025 | 1 year ago |
| RSI: Overbought | Dec 30, 2024 | 1 year ago |
| SMA: Bullish | Nov 25, 2024 | 1 year ago |
| SMA: Bullish | Nov 18, 2024 | 1 year ago |
| SMA: Bearish | Nov 11, 2024 | 1 year ago |
| SMA: Bearish | Nov 4, 2024 | 1 year ago |
| SMA: Bullish | Oct 28, 2024 | 2 years ago |
| SMA: Bullish | Oct 21, 2024 | 2 years ago |
| MACD: Buy Signal | Sep 30, 2024 | 2 years ago |
| SMA: Bearish | Aug 26, 2024 | 2 years ago |
| SMA: Bullish | Aug 19, 2024 | 2 years ago |
| RSI: Oversold | Jul 29, 2024 | 2 years ago |
| RSI: Oversold | Jun 3, 2024 | 2 years ago |
| SMA: Bearish | May 13, 2024 | 2 years ago |
| MACD: Sell Signal | Mar 25, 2024 | 2 years ago |
| SMA: Bearish | Feb 26, 2024 | 2 years ago |
| SMA: Bullish | Dec 25, 2023 | 2 years ago |
| SMA: Bearish | Dec 11, 2023 | 2 years ago |
| SMA: Bullish | Nov 27, 2023 | 2 years ago |
| SMA: Bullish | Nov 27, 2023 | 2 years ago |
| MACD: Buy Signal | Nov 27, 2023 | 2 years ago |
| SMA: Bearish | Oct 23, 2023 | 3 years ago |
| SMA: Bullish | Oct 16, 2023 | 3 years ago |
| RSI: Oversold | Sep 18, 2023 | 3 years ago |
| MACD: Sell Signal | Aug 7, 2023 | 3 years ago |
| SMA: Bearish | Jul 31, 2023 | 3 years ago |
| SMA: Bearish | Jul 31, 2023 | 3 years ago |
| SMA: Bullish | Jul 24, 2023 | 3 years ago |
| SMA: Bearish | Jul 17, 2023 | 3 years ago |
| SMA: Bullish | Jul 10, 2023 | 3 years ago |
| SMA: Bullish | Jul 10, 2023 | 3 years ago |
| SMA: Bearish | Jun 19, 2023 | 3 years ago |
| SMA: Bearish | Jun 19, 2023 | 3 years ago |
| SMA: Bullish | Jun 5, 2023 | 3 years ago |
| SMA: Bearish | May 22, 2023 | 3 years ago |
| SMA: Bearish | May 22, 2023 | 3 years ago |
| SMA: Bullish | May 8, 2023 | 3 years ago |
| SMA: Bearish | May 1, 2023 | 3 years ago |
| SMA: Bullish | Apr 17, 2023 | 3 years ago |
| SMA: Bullish | Apr 17, 2023 | 3 years ago |
| SMA: Bearish | Feb 6, 2023 | 3 years ago |
| SMA: Bearish | Feb 6, 2023 | 3 years ago |
| SMA: Bullish | Jan 30, 2023 | 3 years ago |
| SMA: Bearish | Jan 2, 2023 | 3 years ago |
| SMA: Bullish | Dec 26, 2022 | 3 years ago |
| SMA: Bullish | Dec 19, 2022 | 3 years ago |
| SMA: Bearish | Aug 22, 2022 | 4 years ago |
| RSI: Oversold | Aug 15, 2022 | 4 years ago |
| SMA: Bullish | Aug 1, 2022 | 4 years ago |
| SMA: Bearish | Mar 28, 2022 | 4 years ago |
| SMA: Bullish | Mar 14, 2022 | 4 years ago |
| SMA: Bearish | Feb 14, 2022 | 4 years ago |
| SMA: Bullish | Feb 7, 2022 | 4 years ago |
Key statistics
- Market cap
- 62.16M
- Enterprise value
- 28.55M
- Trailing P/E
- 0.00
- Forward P/E
- -4.48
- PEG ratio
- 0.00
- Price / sales
- 18.63
- Price / book
- 4.21
- EPS (TTM)
- -0.28
- Beta
- 2.63
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 3.34M
- Revenue growth
- 7.90%
- Free cash flow
- -6.62M
- Total cash
- 10.46M
- Total debt
- 520.00K
- Return on equity
- -94.22%
- Shares outstanding
- 55.50M
- Short % of float
- 0.98%
- 50-day average
- 0.74766
- 200-day average
- 0.852735
Analyst view
Consensus: none
Price target (mean) 3.37 +287.0% upside
Now 0.87
- Target (low)
- 2.50
- Target (mean)
- 3.37
- Target (high)
- 4.60
Ratings (0m) 3 3 buy · 0 hold · 0 sell
- Strong buy2
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 20, 2024
Expected Aug 20, 2024. Consensus EPS estimate -0.07.
Financials — quick view
ICCM Revenue — quarterly 907.00K
ICCM Net income — quarterly -4.50M
ICCM EPS — quarterly -1.37
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 26, 2024 | Sep 1, 2024 | -0.07 | -0.08 | -0.01 | -14.29% |
| Aug 20, 2024 | Jun 1, 2024 | -0.07 | — | — | — |
| Aug 20, 2024 | Jun 1, 2024 | -0.07 | -0.06 | +0.01 | +14.29% |
| May 28, 2024 | Mar 1, 2024 | -0.08 | — | — | — |
| May 28, 2024 | Mar 1, 2024 | -0.08 | -0.08 | 0.00 | 0.00% |
| Apr 3, 2024 | Dec 1, 2023 | 0.00 | -0.07 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 27, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 8, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 12, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 21, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Jul 2, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 5, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About IceCure Medical Ltd
IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- Israel
- Website
- icecure-medical.com
News
- IceCure Medical Completes Treatment Of First Patient In Its Post-Marketing Study Evaluating ProSense Cryoablation For Local Treatment Of Low-Risk Breast Cancer
- IceCure Successfully Completes First Cryoablation Treatment in Its ChoICE Post-Marketing Study for Breast Cancer Cryoablation
- 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- IceCure Enrolls First Patients in Its FDA-Approved Study for ProSense® Breast Cancer Cryoablation at Two U.S. Sites
- Nexalin Technology (NASDAQ:NXL) vs. IceCure Medical (NASDAQ:ICCM) Financial Analysis
- IceCure Medical Announces Presentations, Posters And Physician Workshops On Its ProSense Breast Cancer Cryoablation At The European Society Of Breast Imaging Annual Scientific Meeting
- IceCure Highlights Clinical Data and Strong Physician Engagement for ProSense® Breast Cancer Cryoablation at EUSOBI 2026
- IceCure Medical Adds Legacy Health In Portland, Oregon, As New U.S. Clinical Site For Its Post-Marketing ChoICE Study Evaluating Prosense Cryoablation For Treatment Of Low-Risk Breast Cancer
- IceCure Expands ProSense® ChoICE Study for Low-Risk Breast Cancer adding Legacy Health in Portland, OR as U.S. Clinical Site
- IceCure Medical Ltd. (NASDAQ:ICCM) Stock Now Rated “Hold” by Sell-Side Analysts
Your note
Sign in to keep a note on ICCM — it syncs with the Stock Master app.